Khan AN, Asija S, Pendhari J, Purwar R. CAR-T cell therapy in hematological malignancies: Where are we now and where are we heading for? Eur J Haematol [Internet]. 2024;112:6–18. Available from: https://doi.org/10.1111/ejh.14076

Müller F, Boeltz S, Knitza J, Aigner M, Völkl S, Kharboutli S et al. CD19-targeted CAR T cells in refractory antisynthetase syndrome. Lancet [Internet]. 2023;401:815–8. Available from: https://doi.org/10.1016/S0140-6736(23)00023-5

Mougiakakos D, Krönke G, Völkl S, Kretschmann S, Aigner M, Kharboutli S et al. CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med [Internet]. 2021;385:567–9. Available from: https://doi.org/10.1056/NEJMc2107725

ClinicalTrials.gov [Internet]. [cited 2025 Mar 24]. Available from: https://clinicaltrials.gov/ct2/show/NCT01029366

Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J [Internet]. 2021 [cited 2025 Mar 23];11:69. Available from: https://pubmed.ncbi.nlm.nih.gov/33824268/

Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MA et al. Decade-long leukaemia remissions with persistence of CD4 + CAR T cells. Nature [Internet]. 2022 [cited 2025 Mar 23];602:503–9. Available from: https://pubmed.ncbi.nlm.nih.gov/35110735/

Fischer L, Grieb N, Born P, Weiss R, Seiffert S, Boldt A et al. Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma. Leukemia [Internet]. 2024 [cited 2025 Mar 23];38:372–82. Available from: https://pubmed.ncbi.nlm.nih.gov/38184754/

Ayala Ceja M, Khericha M, Harris CM, Puig-Saus C, Chen YY. CAR-T cell manufacturing: Major process parameters and next-generation strategies. J Exp Med [Internet]. 2024 [cited 2025 Mar 23];221. Available from: https://pubmed.ncbi.nlm.nih.gov/38226974/

Turtle CJ, Hanafi L-A, Berger C, Hudecek M, Pender B, Robinson E et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med [Internet]. 2016 [cited 2025 Mar 23];8:355ra116. Available from: https://pubmed.ncbi.nlm.nih.gov/27605551/

Ahmed N, Wesson W, Lutfi F, Porter DL, Bachanova V, Nastoupil LJ et al. Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel. Blood Adv [Internet]. 2024 [cited 2025 Mar 23];8:5346–54. Available from: https://pubmed.ncbi.nlm.nih.gov/39042880/

Frey NV, Porter DL. Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program [Internet]. 2016 [cited 2025 Mar 23];2016:567–72. Available from: https://pubmed.ncbi.nlm.nih.gov/27913530/

Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol [Internet]. 2022 [cited 2025 Mar 23];22:85–96. Available from: https://pubmed.ncbi.nlm.nih.gov/34002066/

Khurana A, Rosenthal AC, Mohty R, Gaddam M, Bansal R, Hathcock MA et al. Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management. Blood Cancer J [Internet]. 2024 [cited 2025 Mar 23];14:136. Available from: https://pubmed.ncbi.nlm.nih.gov/39134524/

Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S et al. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Transplant Cell Ther [Internet]. 2023 [cited 2025 Mar 23];29:438.e1–438.e16. Available from: https://pubmed.ncbi.nlm.nih.gov/36906275/

Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med [Internet]. 2017 [cited 2025 Mar 23];377:2531–44. Available from: https://pubmed.ncbi.nlm.nih.gov/29226797/

Nusbaum KB, Dulmage B, Choi JN, Jaglowski SM, Korman AM. Cutaneous manifestations of chimeric antigen receptor T-cell therapy: An introduction for dermatologists. J Am Acad Dermatol [Internet]. 2022 [cited 2025 Mar 23];87:597–604. Available from: https://pubmed.ncbi.nlm.nih.gov/34293386/

Siddiqi HF, Staser KW, Nambudiri VE. Research techniques made simple: CAR T-cell therapy. J Invest Dermatol [Internet]. 2018;138:2501–4.e1. Available from: https://doi.org/10.1016/j.jid.2018.09.002

Feng K-C, Guo Y-L, Liu Y, Dai H-R, Wang Y, Lv H-Y et al. Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma. J Hematol Oncol [Internet]. 2017;10:4. Available from: https://doi.org/10.1186/s13045-016-0378-7

Bhullar PK, Motaparthi K, Zieman DP, Johnson C, Gurnani P, Sokumbi O. Toxic epidermal necrolysis-like cutaneous toxicity following chimeric antigen receptor T-cell therapy in recurrent large B-cell lymphoma. J Cutan Pathol [Internet]. 2024;51:767–72. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/cup.14687

Storgard R, Dusza S, Shouval R, Scordo M, Markova A. Dermatologic adverse events associated with chimeric antigen receptor T-cell therapy: A pharmacovigilance analysis of the FDA reporting system. Transplant Cell Ther [Internet]. 2024;30:1035.e1–1035.e7. Available from: https://doi.org/10.1016/j.jtct.2024.06.024

Brudno JN, Natrakul DA, Karrs J, Patel N, Maass-Moreno R, Ahlman MA et al. Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30 + lymphomas: results of a phase 1 trial. Blood Adv [Internet]. 2024;8:802–14. Available from: https://doi.org/10.1182/bloodadvances.2023011470

Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu M-F, Ivanova A et al. Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma. J Clin Oncol [Internet]. 2020;38:3794–804. Available from: https://doi.org/10.1200/JCO.20.01342

ClinicalTrials.gov [Internet]. [cited 2025 May 20]. Available from: https://clinicaltrials.gov/ct2/

Qiu L, Zhu F, Wei G, Wu W, Yang L, Hu Y et al. Idiopathic thrombocytopenic purpura treatment in a relapsed/refractory multiple myeloma patient after chimeric antigen receptor T cell therapy. Regen Ther [Internet]. 2020;14:271–4. Available from: https://doi.org/10.1016/j.reth.2020.03.005

Wang Y, Qi K, Cheng H, Cao J, Shi M, Qiao J et al. Coagulation disorders after chimeric antigen receptor T cell therapy: Analysis of 100 patients with relapsed and refractory hematologic malignancies. Biol Blood Marrow Transplant [Internet]. 2020;26:865–75. Available from: https://doi.org/10.1016/j.bbmt.2019.11.027

Matsuo T, Wurster S, Ivan D, Hicklen R, McConn K, Bagwell KA et al. Lethal disseminated mucorales infection with positive blood cultures with purpura fulminans complicating hemophagocytic lymphohistiocytosis after chimeric antigen receptor T-cell therapy. Open Forum Infect Dis [Internet]. 2024;11:ofae647. Available from: https://doi.org/10.1093/ofid/ofae647

Hu Y, Zheng W, Qiao J, Cui Q, Zhu Y, Chang AH et al. Bullous and exanthematous lesions associated with chimeric antigen receptor T-cell therapy in a patient with diffuse large B-cell lymphoma. JAMA Dermatol [Internet]. 2020 [cited 2025 Mar 23];156:1026–8. Available from: https://pubmed.ncbi.nlm.nih.gov/32432646/

Fiorillo G, Toso F, Cortese A, Piscazzi F, Bressan A, Bramanti S et al. Cutaneous toxicity of CAR T-cell therapy: Case report of a bullous life-threatening reaction. J Eur Acad Dermatol Venereol [Internet]. 2023;37:e729–31. Available from: https://doi.org/10.1111/jdv.18892

Khoda F, Ghadiri S, Palmer T, Warburton K. A constellation of cutaneous reactions to chimeric antigen receptor T-cell therapy. Clin Exp Dermatol [Internet]. 2024;50:152–3. Available from: https://doi.org/10.1093/ced/llae311

Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, Harr T. Current perspectives on erythema multiforme. Clin Rev Allergy Immunol [Internet]. 2018;54:177–84. Available from: https://doi.org/10.1007/s12016-017-8667-7

Valks R, Fraga J, Porras-Luque J, Figuera A, Garcia-Diéz A, Fernändez-Herrera J. Chemotherapy-induced eccrine squamous syringometaplasia. A distinctive eruption in patients receiving hematopoietic progenitor cells. Arch Dermatol [Internet]. 1997;133:873–8. Available from: https://doi.org/10.1001/archderm.133.7.873

Ramachandran V, Kolli SS, Strowd LC. Review of graft-versus-host disease. Dermatol Clin [Internet]. 2019;37:569–82. Available from: https://doi.org/10.1016/j.det.2019.05.014

Strong Rodrigues K, Oliveira-Ribeiro C, de Abreu Fiuza Gomes S, Knobler R. Cutaneous graft-versus-host disease: Diagnosis and treatment. Am J Clin Dermatol [Internet]. 2018;19:33–50. Available from: https://link.springer.com/content/pdf/https://doi.org/10.1007/s40257-017-0306-9.pdf

Maity S, Banerjee I, Sinha R, Jha H, Ghosh P, Mustafi S. Nikolsky’s sign: A pathognomic boon. J Family Med Prim Care [Internet]. 2020;9:526–30. Available from: https://pubmed.ncbi.nlm.nih.gov/32318376/

Dowling JR, Anderson KL, Huang WW. Asboe-Hansen sign in toxic epidermal necrolysis. Cutis [Internet]. 2019;103:E6–8. Available from: https://pubmed.ncbi.nlm.nih.gov/31116821/

Awad A, Goh MS, Trubiano JA. Drug reaction with eosinophilia and systemic symptoms: A systematic review. J Allergy Clin Immunol Pract [Internet]. 2023;11:1856–68. Available from: https://pubmed.ncbi.nlm.nih.gov/36893848/

Li S, Ringus D, Grammer L. Cutaneous manifestations of cytokine release syndrome following car-t cell therapy. Ann Allergy Asthma Immunol [Internet]. 2024;133:S105–6. Available from: https://www.sciencedirect.com/science/article/pii/S108112062401010X

Austad SS, Athalye L. Exfoliative dermatitis. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Mar 11]. Available from: https://pubmed.ncbi.nlm.nih.gov/32119455/

Goodman RS, Johnson DB, Balko JM. Corticosteroids and cancer immunotherapy. Clin Cancer Res [Internet]. 2023 [cited 2025 Mar 23];29:2580–7. Available from: https://pubmed.ncbi.nlm.nih.gov/36648402/

Masucci C, Pepe S, La Rocca U, Zullino V, De Propris MS, Barberi W et al. Case Report: Severe cutaneous adverse event associated with checkpoint inhibition in the setting of CAR T-cell therapy: beyond CRS. Front Oncol [Internet]. 2023;13:1171031. Available from: https://www.frontiersin.org/articles/https://doi.org/10.3389/fonc.2023.1171031/full

Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA et al. FDA approval summary: Tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist [Internet]. 2018;23:943–7. Available from: https://academic.oup.com/oncolo/article-abstract/23/8/943/6439647

Riegler LL, Jones GP, Lee DW. Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy. Ther Clin Risk Manag [Internet]. 2019;15:323–35. Available from: https://www.tandfonline.com/doi/abs/10.2147/TCRM.S150524

Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med [Internet]. 2013 [cited 2025 Mar 23];368:1509–18. Available from: https://pubmed.ncbi.nlm.nih.gov/23527958/

Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood [Internet]. 2014 [cited 2025 Mar 23];124:188–95. Available from: https://pubmed.ncbi.nlm.nih.gov/24876563/

Naik PP. A contemporary snippet on clinical presentation and management of toxic epidermal necrolysis. Scars Burn Heal [Internet]. 2022 [cited 2025 Mar 23];8:20595131221122381. Available from: https://pubmed.ncbi.nlm.nih.gov/36118413/

Schneider JA, Cohen PR. Stevens-Johnson syndrome and toxic epidermal necrolysis: A concise review with a comprehensive summary of therapeutic interventions emphasizing supportive measures. Adv Ther [Internet]. 2017 [cited 2025 Mar 23];34:1235–44. Available from: https://pubmed.ncbi.nlm.nih.gov/28439852/

Kumar R, Das A, Das S. Management of Stevens-Johnson syndrome-toxic epidermal necrolysis: Looking beyond guidelines! Indian J Dermatol [Internet]. 2018 [cited 2025 Mar 23];63:117–24. Available from: https://pubmed.ncbi.nlm.nih.gov/29692452/

Mistry N, Gupta A, Alavi A, Sibbald RG. A review of the diagnosis and management of erythroderma (generalized red skin). Adv Skin Wound Care [Internet]. 2015;28:228–36; quiz 237–8. Available from: https://pubmed.ncbi.nlm.nih.gov/25882661/

Tóth G, Lukács A, Schirra F, Sándor GL, Killik P, Maneschg OA et al. Ophthalmic aspects of Stevens-Johnson syndrome and toxic epidermal necrolysis: A narrative review. Ophthalmol Ther [Internet]. 2023 [cited 2025 Mar 23];12:1795–811. Available from: https://pubmed.ncbi.nlm.nih.gov/37140876/

Paulmann M, Heuer R, Annecke T, Behr B, Boch K, Boos AM et al. S3 guideline: Diagnosis and treatment of epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis) - Part 2: Supportive therapy of EN in the acute and post-acute stages. J Dtsch Dermatol Ges [Internet]. 2024 [cited 2025 Mar 23];22:1576–93. Available from: https://pubmed.ncbi.nlm.nih.gov/39417754/

Navrotski BR, de Nihi F, Camilleri FM, Cerci MJ. FB. Wet wrap dressings as a rescue therapy option for erythrodermic psoriasis. An Bras Dermatol [Internet]. 2018 [cited 2025 Mar 23];93:598–600. Available from: https://pubmed.ncbi.nlm.nih.gov/30066777/

Wan J. Atopic Dermatitis and Erythroderma. Inpatient dermatology Cham: Springer Internat Publ [Internet]. 2018;299–302. Available from: https://books.google.com/books?hl=enamp;lr=amp;id=vQJ2DwAAQBAJamp;oi=fndamp;pg=PA299amp;dq=wet+wraps+erythrodermaamp;ots=1PmEezlIpNamp;sig=sMrUFNkyMtZfjbKiv3ErqsGO_Lk

Castillo B, Vera N, Ortega-Loayza AG, Seminario-Vidal L. Wound care for Stevens-Johnson syndrome and toxic epidermal necrolysis. J Am Acad Dermatol [Internet]. 2018;79:764–7.e1. Available from: https://www.jaad.org/article/S0190-9622(18)30486-9/abstract